Mechanism of Action:
- Potent dual agonist with maximum affinity for GLP-1 and glucagon receptors
- Provides significant appetite suppression through direct effects on hunger centers in CNS
- Substantially increases thermogenesis and energy expenditure
- Improves pancreatic β-cell function
- Reduces insulin resistance in liver and peripheral tissues
Recommended for:
- Patients with super obesity (BMI > 40)
- Type 2 diabetes patients with decompensation on combination therapy
- Individuals with metabolic syndrome and high cardiovascular risk
- Preparation for bariatric surgery
- Patients with non-alcoholic steatohepatitis
Research and Studies:
Extended clinical studies demonstrate:
- 22-26% weight loss over 48 weeks of therapy
- HbA1c normalization (<6.5%) in 65% of diabetic patients
- Improvement in liver histology in NAFLD
- 25-30% reduction in cardiovascular risk
- Long-term maintenance of achieved results
- Super obesity (BMI ≥ 40 kg/m²)
- Decompensated type 2 diabetes
- Metabolic syndrome with high cardiovascular risk
- Non-alcoholic steatohepatitis
- Preparation for bariatric surgery
The drug is dissolved in appropriate volume of sterile water for injections and administered subcutaneously in the abdominal area. Treatment starts with dose of 5 mg once weekly, with gradual dose titration of 5 mg every 4 weeks until maximum therapeutic dose of 30 mg per week is reached. For maintenance of achieved results, long-term use under medical supervision is possible.
Contraindications:
- Type 1 diabetes mellitus
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia type 2
- Recurrent acute pancreatitis
- Severe hepatic failure (Child-Pugh C)
Side Effects:
- Significant gastrointestinal symptoms during titration period
- Dehydration with insufficient fluid intake
- Cholelithiasis
- Increased heart rate
- Risk of acute pancreatitis
